GlassScriptPhysician profile
Frances Pach
NPI 1457584682
$3,822.46
in general payments reported to CMS, 2019-2025
20 companies · $1,465 in 2025
The $1,465 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $946 · 2022: $812 · 2023: $479 · 2024: $120 · 2025: $1,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,063.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $618.81 | 2021-2022 | |
| Amgen INC. | $362.52 | 2021-2025 | |
| Glaxosmithkline, LLC. | $332.55 | 2025 | |
| Edwards Lifesciences Corporation | $311.79 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Biohaven Pharmaceuticals, INC. | $250.00 | 2021 | |
| Neurelis, INC. | $249.27 | 2023-2025 | Valtoco |
| Abbvie INC. | $241.07 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $234.61 | 2022 | |
| Sunovion Pharmaceuticals INC. | $142.11 | 2021 | |
| Gilead Sciences, INC. | $136.85 | 2025 | Yeztugo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.52 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $121.63 | 2025 | Dojolvi |
| Axsome Therapeutics, INC. | $121.43 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $120.79 | 2021 | |
| Novo Nordisk INC | $120.39 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $107.06 | 2025 | Nimbl, Flexitouch Plus |
| Pfizer INC. | $98.65 | 2025 | |
| Biogen, INC. | $92.72 | 2023 | |
| Aquestive Therapeutics, INC. | $23.49 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Pach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.